Information and Services

Announcement on Early Termination of GV-971 Global Multi-Center Phase III Clinical Trial

Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate’s Global Phase II Clinical Trial in Treating Parkinson’s Disease

GV-971 Gets Included in China National Reimbursement Drug List

GV-971 Global Phase III Clinical Trial Officially Initiates in Greater China to Clarify Its Potential in Changing Disease Course

Nature Index-China: Alzheimer’s drug trial explores gut-brain link

Cell-Stanford University Beyond the Textbook Pattern: A Brand-new Biomolecule!

Alzheimer’s Disease Care Project Initiates to Provide Long-term Benefits to Patients

GV-971 Global Phase III Clinical Trial Completes First Patient Dosed Globally

GV-971 Global Multi-center Phase III Clinical Trial Kicks-off Patient Enrollment Process

Green Valley Obtains IND Approval from U.S. FDA for GV-971 Global Phase III Clinical Trial

GV-971 Was Awarded Top10 Novel Drugs in the 13th Health China Forum

GV-971 Officially Launched in China

Nature Announced Ones to Watch in 2020 and Meiyu Geng Got Selected

Green Valley Announces NMPA Approval Of Oligomannate For Mild To Moderate Alzheimer's Disease

Cell Research: Latest Progress of the Drug Reshaping Gut Microbiota to Inhibit Alzheimer Disease in Mice

GV-971 Novel Mechanism of Action Results Featured on the Cover of Cell Research

Green Valley Announced Promising Findings from a Phase 3 Clinical Trial of GV-971